Enlivex to Present Key Results from Osteoarthritis Trial

An update from Enlivex ( (ENLV) ) is now available.

On August 14, 2025, Enlivex Therapeutics announced it will host a webinar on August 18, 2025, to present 3-month topline results from the Phase IIa stage of its ENX-CL-05-001 trial. This trial is a double-blind, randomized, placebo-controlled study evaluating Allocetra™ in patients with moderate-to-severe knee osteoarthritis. The interim analysis aims to assess the potential benefits of expanding the trial’s enrollment and identifying responder sub-populations. The results could impact Enlivex’s operations and industry positioning by demonstrating the efficacy and safety of Allocetra™ in treating osteoarthritis, potentially influencing stakeholder decisions.

The most recent analyst rating on (ENLV) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Enlivex stock, see the ENLV Stock Forecast page.

Spark’s Take on ENLV Stock

According to Spark, TipRanks’ AI Analyst, ENLV is a Underperform.

Enlivex’s financial challenges, characterized by no revenue and ongoing cash burn, significantly impact its stock score. Technical indicators show neutral momentum, but the negative valuation metrics reflect ongoing financial difficulties. The absence of positive corporate events or earnings call data limits the potential for a higher score.

To see Spark’s full report on ENLV stock, click here.

More about Enlivex

Enlivex Therapeutics Ltd. is a clinical-stage company specializing in macrophage reprogramming immunotherapy. The company is focused on developing Allocetra™, a universal, off-the-shelf cell therapy aimed at reprogramming macrophages into their homeostatic state to address life-threatening and debilitating conditions.

Average Trading Volume: 188,526

Technical Sentiment Signal: Hold

Current Market Cap: $37.44M

Learn more about ENLV stock on TipRanks’ Stock Analysis page.